舍曲林治疗夜间进食综合征的临床试验。
Clinical trial of sertraline in the treatment of night eating syndrome.
作者信息
O'Reardon John P, Stunkard Albert J, Allison Kelly C
机构信息
Department of Psychiatry, Weight and Eating Disorders Program, University of Pennsylvania, Philadelphia, 19104, USA.
出版信息
Int J Eat Disord. 2004 Jan;35(1):16-26. doi: 10.1002/eat.10224.
OBJECTIVE
To test the efficacy of sertraline in the treatment of night eating syndrome.
METHODS
Seventeen patients meeting criteria for night eating syndrome received sertraline in a 12-week open-label, nonblind trial. Outcome was assessed by four primary measures, namely, the number of nocturnal awakenings, the number of ingestions, total daily caloric intake after the evening meal, and an overall rating of change from the Clinical Global Impression of Improvement scale (CGI-I).
RESULTS AND DISCUSSION
An intent-to-treat analysis revealed highly significant improvements across all four primary outcome measures for all 17 subjects. Five subjects achieved full remission of symptoms (CGI-I score of 1 = very much improved) and lost a significant amount of weight over the course of the study (-4.8 +/- 2.6 kg, p < .05). Sertraline, a selective serotonin reuptake inhibitor, may be beneficial in the treatment of night eating syndrome.
目的
检验舍曲林治疗夜间进食综合征的疗效。
方法
17名符合夜间进食综合征标准的患者在一项为期12周的开放标签、非盲试验中接受舍曲林治疗。通过四项主要指标评估结果，即夜间觉醒次数、进食次数、晚餐后每日总热量摄入，以及临床总体印象改善量表（CGI-I）的总体变化评分。
结果与讨论
意向性分析显示，所有17名受试者的四项主要结局指标均有高度显著改善。5名受试者症状完全缓解（CGI-I评分为1 = 显著改善），且在研究过程中体重显著下降（-4.8 +/- 2.6千克，p < .05）。舍曲林作为一种选择性5-羟色胺再摄取抑制剂，可能对治疗夜间进食综合征有益。
Zotero 插件